Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treating In-Hospital Stroke—Reply

Treating In-Hospital Stroke—Reply Letters Conflict of Interest Disclosures: None reported. proportions of stroke mimics and treatment contraindica- Funding/Support: Dr Pascual is supported by National Institutes of Health tions in hospitalized patients. In addition to having a stan- grants NS077015, NS078059, RR002584, and RR024982. dardized in-hospital stroke code protocol, training all hospi- Role of the Funder/Sponsor: The National Institutes of Health had no role in tal personnel in accurate stroke recognition will help improve the design and conduct of the study; collection, management, analysis, and the identification of those patients appropriate for intrave- interpretation of the data; preparation, review, or approval of the manuscript; nous tissue plasminogen activator or endovascular therapy and and decision to submit the manuscript for publication. optimize resource use. 1. Kirkorian Y, Cohen B. Incontinentia Pigmenti. In: Rosenberg RN, Pascual JM, eds. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. San Diego, CA: Academic Press; 2015. Nada El Husseini, MD, MHSc 2. Minić S, Trpinac D, Obradović M. Incontinentia pigmenti diagnostic criteria Larry B. Goldstein, MD update. Clin Genet. 2014;85(6):536-542. 3. Phan TA, Wargon O, Turner AM. Incontinentia pigmenti case series: clinical Author Affiliations: Wake Forest Baptist Medical Center, Winston Salem, North spectrum of incontinentia pigmenti in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Treating In-Hospital Stroke—Reply

Saltman, Alexandra P.; Kapral, Moira K.
JAMA Neurology , Volume 72 (12) – Dec 1, 2015
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/treating-in-hospital-stroke-reply-Lk0JSClENd

References (5)

Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2015.2669
pmid
26658973
Publisher site
See Article on Publisher Site

Abstract

Letters Conflict of Interest Disclosures: None reported. proportions of stroke mimics and treatment contraindica- Funding/Support: Dr Pascual is supported by National Institutes of Health tions in hospitalized patients. In addition to having a stan- grants NS077015, NS078059, RR002584, and RR024982. dardized in-hospital stroke code protocol, training all hospi- Role of the Funder/Sponsor: The National Institutes of Health had no role in tal personnel in accurate stroke recognition will help improve the design and conduct of the study; collection, management, analysis, and the identification of those patients appropriate for intrave- interpretation of the data; preparation, review, or approval of the manuscript; nous tissue plasminogen activator or endovascular therapy and and decision to submit the manuscript for publication. optimize resource use. 1. Kirkorian Y, Cohen B. Incontinentia Pigmenti. In: Rosenberg RN, Pascual JM, eds. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. San Diego, CA: Academic Press; 2015. Nada El Husseini, MD, MHSc 2. Minić S, Trpinac D, Obradović M. Incontinentia pigmenti diagnostic criteria Larry B. Goldstein, MD update. Clin Genet. 2014;85(6):536-542. 3. Phan TA, Wargon O, Turner AM. Incontinentia pigmenti case series: clinical Author Affiliations: Wake Forest Baptist Medical Center, Winston Salem, North spectrum of incontinentia pigmenti in

Journal

JAMA Neurology – American Medical Association

Published: Dec 1, 2015

There are no references for this article.